163 related articles for article (PubMed ID: 27432462)
1. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
[TBL] [Abstract][Full Text] [Related]
2. Impact of transitioning inpatient chemotherapy regimens to the outpatient setting.
Corsi MP; Shea K; W Knoebel R
J Oncol Pharm Pract; 2020 Sep; 26(6):1324-1330. PubMed ID: 31822200
[TBL] [Abstract][Full Text] [Related]
3. Making moves: Transitioning R-EPOCH to the ambulatory setting.
Martin AL; Frank JP; Waggoner ML
J Oncol Pharm Pract; 2018 Dec; 24(8):617-622. PubMed ID: 28782408
[TBL] [Abstract][Full Text] [Related]
4. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment.
Herold M; Hieke K
Value Health; 2003; 6(2):167-74. PubMed ID: 12641867
[TBL] [Abstract][Full Text] [Related]
5. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
6. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
[TBL] [Abstract][Full Text] [Related]
7. Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications.
Beaty RS; Bernhardt MB; Berger AH; Hesselgrave JE; Russell HV; Okcu MF
Pediatr Blood Cancer; 2015 Nov; 62(11):1925-8. PubMed ID: 26152314
[TBL] [Abstract][Full Text] [Related]
8. Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital.
Keshvani N; Hon M; Gupta A; Brown TJ; Roy L; Marley E; Lindsey S; Johnson DH; Sadeghi N; Li HC
J Oncol Pract; 2019 Aug; 15(8):e644-e651. PubMed ID: 31206340
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
[TBL] [Abstract][Full Text] [Related]
10. Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin's lymphoma.
Roder L; Konrardy K; Grauer D; Hoffmann M
Support Care Cancer; 2021 Sep; 29(9):5075-5082. PubMed ID: 33594515
[TBL] [Abstract][Full Text] [Related]
11. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center.
Li W; Richter KA; Tobon KA; McCarthy KT; Kubal TE
J Oncol Pharm Pract; 2021 Oct; 27(7):1684-1690. PubMed ID: 33092499
[TBL] [Abstract][Full Text] [Related]
12. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting.
Okello CD; Omoding A; Ddungu H; Mulumba Y; Orem J
BMC Cancer; 2020 Aug; 20(1):798. PubMed ID: 32831073
[TBL] [Abstract][Full Text] [Related]
15. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
[TBL] [Abstract][Full Text] [Related]
16. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
17. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH
J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436
[TBL] [Abstract][Full Text] [Related]
18. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
Dranitsaris G; Altmayer C; Quirt I
Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
[TBL] [Abstract][Full Text] [Related]
20. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]